A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers

Acellular dermal matrices can successfully heal wounds. This study's goal was to compare clinical outcomes of a novel, open‐structure human reticular acellular dermis matrix ( HR‐ADM ) to facilitate wound closure in non‐healing diabetic foot ulcers ( DFUs ) versus DFUs treated with standard of care ( SOC ). Following a 2‐week screening period in which DFUs were treated with offloading and moist wound care, patients were randomised to either SOC...